A health innovation minister has admitted that public mistrust of Palantir may be driving a rise in NHS data opt-outs, just as ministers soften their stance on whether trusts must use the company’s Federated Data Platform.

NHS Data Opt-Outs Rise As Minister Admits Palantir “Mistrust” Risk

There is a particular kind of data loss that does not show up in a breach notification or a system outage log. It shows up, slowly, as thousands of individual decisions by patients to withdraw consent for their records to be used in research and planning. Between mid-May and mid-July this year, roughly 60,000 more people in England did exactly that under the national data opt-out mechanism. James Frith, the health innovation minister, has now linked that rise directly to what he called mistrust of Palantir, the US data analytics firm at the centre of the NHS Federated Data Platform.

Frith’s admission, made in a letter to Layla Moran, chair of the Commons health committee, lands at an awkward moment for a contract that has already outlasted one prime minister. Ministers ordered a full review of the £330 million deal back in June, after a Science, Innovation and Technology Committee report named Palantir the most concerning technology supplier operating across UK public services, with a break clause due in early 2027. The opt-out figures suggest patients are not waiting for that review’s outcome.

What The Opt-Out Rise Actually Means For Data-Driven Care

It is worth being precise about what is and is not at stake here. Opting out does not affect direct care. A GP or community nurse still sees a patient’s notes, referrals and test results exactly as before. What disappears is the aggregated data that underpins population health management, service planning and the analytics that integrated care boards increasingly rely on to target resources at the people most likely to need them. For a sector that has spent several years building remote monitoring, electronic care planning and predictive discharge tools on the promise of richer shared data, a steady drift towards non-consent is a slow puncture rather than a blowout, but a puncture all the same.

Frith described the rise as modest, and in raw percentage terms it is. But the ten-year health plan’s ambitions for prevention, workforce modelling and AI-assisted diagnostics depend on a baseline of trust that cannot simply be legislated back into existence once lost. That much was already clear back in June, when Keir Starmer’s resignation left the Palantir contract as one of the most contested pieces of unfinished business in his NHS record, and it has taken barely six months for the same row to resurface under new leadership.

A Softening Mandate Gives Integrated Care Boards Real Choices

The more consequential shift buried in Frith’s letter is not the opt-out figure but a change in tone on whether trusts are obliged to use the Federated Data Platform at all. As recently as July, a health minister told Parliament that trusts “must use” parts of the platform. Frith has now said there is no requirement to do so, and that boards may prefer an alternative. The Department of Health and Social Care insists this represents no change in position, arguing the FDP has never been mandatory, a claim that sits uneasily alongside the review ministers themselves ordered into the £330 million contract ahead of the 2027 break clause decision. Whichever account is more accurate, the practical effect is the same: integrated care boards weighing up domiciliary care technology, community health platforms or homegrown alternatives now have clearer political cover to look elsewhere.

Implications For Commissioners And Care Technology Suppliers

For registered care providers and the technology companies that serve them, this is not an abstract Whitehall dispute. Greater Manchester’s integrated care board has already declined to adopt the platform, and its stance is likely to be tested by other systems watching how the review unfolds. Domiciliary and residential providers procuring care planning or monitoring tools that plug into NHS data infrastructure now face a genuine question about which platform, or combination of platforms, will still be standing after 2027. Suppliers pitching interoperable, standards-based alternatives to a single dominant vendor may find commissioners more receptive than they were twelve months ago.

The statistics watchdog’s ongoing review of Palantir’s own operational claims, including its figures on discharge delays and cancer diagnosis timescales, will shape how much political cover the company retains. Yvette Cooper inherited this decision along with the rest of her health brief in July, and how she chooses to handle NHS digital transformation’s biggest unresolved row will say a great deal about the direction her department takes on large US data contractors. Moran has called the softened mandate welcome but insufficient, pressing for a decision on switching providers well before February. The care technology sector’s task in the meantime is less about picking a winner and more about building systems that do not depend on any single supplier surviving the next eighteen months.